Physician profile
Jay Patel
NPI 1467834044
$6,193.21
in general payments reported to CMS, 2019-2025
38 companies · $2,440 in 2025
The $2,440 reported for 2025 was more than what 79% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2022: $728 · 2023: $1,279 · 2024: $1,496 · 2025: $2,440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,105 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,105.31 |
| Education | $110.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,819.95 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $482.71 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Shionogi INC | $365.14 | 2024-2025 | Fetroja |
| Takeda Pharmaceuticals U.S.A., INC. | $341.38 | 2022-2025 | Glassia, Hyqvia, Cuvitru |
| Boehringer Ingelheim Pharmaceuticals, INC. | $329.89 | 2023-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Genzyme Corporation | $310.47 | 2022-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $259.11 | 2025 | Lumryz |
| Grifols USA, LLC | $178.85 | 2022-2025 | Prolastin-C Liquid |
| Pulmonx Corporation | $178.83 | 2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Stryker Corporation | $151.03 | 2025 | Flowtriever |
| Gilead Sciences, INC. | $124.93 | 2019 | |
| Jazz Pharmaceuticals INC. | $118.51 | 2022 | |
| Intuitive Surgical, INC. | $114.21 | 2022-2024 | |
| Boston Scientific Corporation | $106.78 | 2025 | Emerge Push |
| Mylan Specialty L.P. | $102.68 | 2023-2024 | Yupelri |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $99.45 | 2025 | Lifevest |
| Lilly USA, LLC | $79.67 | 2024-2025 | Zepbound, Trulicity, Mounjaro |
| Itamar Medical INC | $77.88 | 2025 | Watchpatone |
| Paratek Pharmaceuticals, INC. | $74.98 | 2024-2025 | Nuzyra |
| Actelion Pharmaceuticals US, INC. | $72.77 | 2023-2024 | Opsumit, Uptravi |
| United Therapeutics Corporation | $67.65 | 2023-2025 | Tyvaso, Tyvaso |
| Harmony Biosciences LLC | $65.99 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $65.34 | 2024-2025 | Dupixent |
| Insmed, INC. | $62.88 | 2023-2025 | Arikayce |
| Axsome Therapeutics, INC. | $62.36 | 2024-2025 | Sunosi |
| Verona Pharma, INC. | $60.34 | 2025 | Ohtuvayre |
| Amgen INC. | $59.34 | 2024 | Tavneos |
| Vifor Pharma, INC. | $51.42 | 2025 | Zemaira |
| Resmed Corp | $44.22 | 2025 | |
| Janssen Pharmaceuticals, INC | $38.45 | 2023-2024 | Xarelto |
| Novo Nordisk INC | $35.98 | 2023 | Wegovy, Saxenda |
| Philips North America LLC | $34.80 | 2024-2025 | Dreamwear 7200 Sp Mask, (Ak6) Vest Therapy |
| Covis Pharma Gmbh | $31.86 | 2023 | |
| Almatica Pharma LLC | $30.66 | 2023 | Loreev Xr |
| Abbvie INC. | $26.93 | 2025 | |
| Merck Sharp & Dohme LLC | $25.28 | 2025 | Gardasil 9, Capvaxive |
| Exact Sciences Corporation | $21.70 | 2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.79 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.